Acute myocardial infarction

  title={Acute myocardial infarction},
  author={Grant W. Reed and Jeffrey E Rossi and Christopher P. Cannon},
  journal={The Lancet},

Figures and Tables from this paper

ST-segment elevation myocardial infarction
Primary percutaneous coronary intervention (PCI) has become the preferred reperfusion strategy in patients with STEMI; if PCI cannot be performed within 120 minutes of STEMI diagnosis, fibrinolysis therapy should be administered to dissolve the occluding thrombus.
Reperfusion Strategies in Acute Myocardial Infarction: State of the Art
  • F. O. Rangel
  • Medicine
    International Journal of Cardiovascular Sciences
  • 2021
A systematic review of different reperfusion strategies for STEMI was conducted, including randomized controlled trials that included major cardiovascular events (MACE), and systematic reviews in the last 5 years through the PRISMA ( Preferred Reporting Items for Systematic Reviews and Meta-Analysis) methodology.
Therapeutic Peptides to Treat Myocardial Ischemia-Reperfusion Injury
Therapeutic peptides will be presented depending on their interacting mechanisms (apoptosis, necroptosis, and inflammation) reported as playing an important role in reperfusion injury following myocardial ischemia, to develop new cardioprotective strategies to decrease morbidity/mortality of CVD.
Diagnosis and Treatment of Acute Coronary Syndromes: A Review.
In high-risk patients with NSTE-ACS and no contraindications, prompt invasive coronary angiography and percutaneous or surgical revascularization within 24 to 48 hours are associated with a reduction in death from 6.5% to 4.9%.
Myocardial perfusion scintigraphy in myocardial infarction — impact of ST-segment elevation and of Diabetes mellitus
The presence of ST-segment elevation but not the presence of Diabetes mellitus is associated with different patterns of MPS in patients with MI, with significantly larger values both for percentage and absolute areas of perfusion defects both at rest and in a stress situation.
The diagonal branches and outcomes in patients with anterior ST- elevation myocardial infarction
Landmark analysis indicated that the significant differences in 18-month outcomes between the two groups mainly resulted from the differences during the hospitalization, and multivariate Cox proportional hazards analysis found that D flow loss before primary PCI was independent factor predicting short- and long-term outcomes in patients with anterior STEMI.
Targeting Inflammation After Myocardial Infarction
In patients with AMI, modulation of residual inflammation via various inflammatory pathways and mediators may hold promise for further reducing MACE.
Culprit vessel-related myocardial mechanics and prognostic implications following acute myocardial infarction
CMR allows IRA-specific phenotyping and characterisation of morphologic and functional changes that carry infarct-specific prognostic implications, and may represent novel diagnostic and therapeutic targets following AMI.


Randomized trial of preventive angioplasty in myocardial infarction.
In patients with STEMI and multivessel coronary artery disease undergoing infarct-artery PCI, preventive PCI in noninfarct coronary arteries with major stenoses significantly reduced the risk of adverse cardiovascular events, as compared with PCI limited to the infarCT artery.
Thrombus aspiration during ST-segment elevation myocardial infarction.
Routine thrombus aspiration before PCI as compared with PCI alone did not reduce 30-day mortality among patients with STEMI, and results were consistent across all major prespecified subgroups, including subgroups defined according toThrombus burden and coronary flow before PCI.
Early versus delayed invasive intervention in acute coronary syndromes.
Early intervention did not differ greatly from delayed intervention in preventing the primary outcome, but it did reduce the rate of the composite secondary outcome of death, myocardial infarction, or refractory ischemia and was superior to delayed Intervention in high-risk patients.
Bivalirudin during primary PCI in acute myocardial infarction.
In patients with ST-segment elevation myocardial infarction who are undergoing primary PCI, anticoagulation with bivalirudin alone, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, results in significantly reduced 30-day rates of major bleeding and net adverse clinical events.
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Cangrelor significantly reduced the rate of ischemic events, including stent thrombosis, during PCI, with no significant increase in severe bleeding.